December 10, 2020 09:00 - 10:15 ET
In this five-part series we will bring together expertise from across the firm to cover developments that span the complete lifecycle of this industry’s complex business model—from financing and procurement to regulation and litigation.
The pandemic has been a turning point for investment in life sciences. What does this mean for investors as well as life sciences companies looking to find opportunity in the industry? In the final webinar of our series, our corporate and capital markets lawyers from Toronto, New York and Calgary—Cheryl Reicin, Chris Bornhorst and Mike Pedlow—unpack the current state of financing for life science companies. The panel will discuss seed investments, venture capital, and public offerings both from Canadian and U.S. perspectives.
9:00 a.m. Webinar opens
9:15 - 10:15 a.m. Presentation
Ontario: This program is eligible for up to 1.0 Substantive hour.
New York: This program contains 1.0 Areas of Professional Practice Credit.
Sessions in this series:
Session 1: Navigating (and challenging) a changing life sciences regulatory environment
Session 2: Life sciences product liability litigation: managing risks and anticipating trends
Session 3: The latest developments in life sciences IP litigation
Session 4: Life sciences and centralized procurement: navigating the process and responding to RFPs
Session 5: Financing life sciences on both sides of the border